Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Active, not recruiting · NCT03920007 · Registry updated 2026-08-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D | Eye Diseases, Hereditary, Leber congenital amaurosis, Leber congenital amaurosis 1, cone-rod dystrophy 6, eye disorder, littoral cell angioma of the spleen, retinal disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-03 | NCT03920007 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Atsena Therapeutics Inc. | 2 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Casey Eye Institute - Oregon Health & Science University | Portland | United States | 4 |
| Scheie Eye Institute, University of Pennsylvania | Philadelphia | United States | 1 |